MCID: UTR011
MIFTS: 34

Uterine Corpus Serous Adenocarcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Serous Adenocarcinoma

Aliases & Descriptions for Uterine Corpus Serous Adenocarcinoma:

Name: Uterine Corpus Serous Adenocarcinoma 12 14
Uterine Papillary Serous Carcinoma 12
Endometrial Serous Adenocarcinoma 69
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 47 C27838
UMLS 69 C1336921

Summaries for Uterine Corpus Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Uterine Corpus Serous Adenocarcinoma, also known as uterine papillary serous carcinoma, is related to uterine corpus endometrial stromal sarcoma and cystinosis, nephropathic. An important gene associated with Uterine Corpus Serous Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Glioma and Pathways in cancer. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Related phenotypes are Decreased viability with cisplatin and Synthetic lethal with cisplatin

Related Diseases for Uterine Corpus Serous Adenocarcinoma

Diseases related to Uterine Corpus Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 uterine corpus endometrial stromal sarcoma 10.2 BRCA1 TP53
2 cystinosis, nephropathic 10.2 ERBB2 TP53
3 adult central nervous system mature teratoma 10.2 ERBB2 TP53
4 central nervous system mature teratoma 10.2 ERBB2 TP53
5 intraorbital meningioma 10.2 BRCA1 TP53
6 oro-mandibular-limb hypogenesis syndrome 10.2 ERBB2 TP53
7 primary hyperoxaluria 10.2 ERBB2 TP53
8 histiocytic and dendritic cell cancer 10.1 BRCA1 ERBB2
9 acquired hemangioma 10.1 ERBB2 TP53
10 male reproductive organ benign neoplasm 10.1 ERBB2 TP53
11 central nervous system primitive neuroectodermal neoplasm 10.1 ERBB2 TP53
12 reactive arthritis 10.1 ERBB2 TP53
13 growth retardation hydrocephaly lung hypoplasia 10.1 ERBB2 TP53
14 arthus reaction 10.1 ERBB2 TP53
15 peroxisome biogenesis disorder 5b 10.1 BRCA1 TP53
16 tamoxifen-related endometrial lesion 10.1 ERBB2 TP53
17 aorto-ventricular tunnel 10.1 BRCA1 BRCA2
18 burn scar 10.1 BRCA1 BRCA2
19 lethal congenital contracture syndrome 7 10.1 BRCA1 BRCA2
20 autoimmune disease of cardiovascular system 10.1 BRCA1 BRCA2
21 heart malignant hemangiopericytoma 10.1 BRCA1 BRCA2
22 bronchogenic cyst 10.1 BRCA1 BRCA2
23 his bundle tachycardia 10.1 ERBB2 TP53
24 bronchiectasis oligospermia 10.1 BRCA1 BRCA2
25 chronic endophthalmitis 10.1 BRCA1 BRCA2
26 neuropathy, distal hereditary motor, type viib 10.1 BRCA1 BRCA2
27 vulva adenocarcinoma 10.1 ERBB2 TP53
28 eccrine sweat gland neoplasm 10.1 BRCA1 BRCA2
29 organ system benign neoplasm 10.1 BRCA1 ERBB2
30 frontal sinusitis 10.1 BRCA1 BRCA2
31 bacteremia 10.1 BRCA1 BRCA2
32 fallopian tube adenocarcinoma 10.1 ERBB2 TP53
33 syndromic x-linked intellectual disability 14 10.1 BRCA1 BRCA2
34 submucosal invasive colon adenocarcinoma 10.1 BRCA2 TP53
35 progesterone-receptor negative breast cancer 10.1 ERBB2 TP53
36 splenic infarction 10.1 ERBB2 TP53
37 pneumonia 10.1 BRCA1 BRCA2
38 herpes simplex encephalitic 6 10.0 BRCA2 TP53
39 nasal cavity adenocarcinoma 10.0 BRCA2 ERBB2
40 prostatic adenoma 10.0 ERBB2 TP53
41 childhood teratocarcinoma of the testis 10.0 BRCA1 BRCA2
42 postpartum depression 10.0 BRCA1 ERBB2 TP53
43 mediastinum angiosarcoma 10.0 ERBB2 TP53
44 breast malignant phyllodes tumor 10.0 BRCA1 ERBB2 TP53
45 paroxysmal nocturnal hemoglobinuria 10.0 BRCA2 TP53
46 breast pericanalicular fibroadenoma 10.0 BRCA1 BRCA2 TP53
47 villoglandular endometrial endometrioid adenocarcinoma 10.0 BRCA1 BRCA2 TP53
48 paraphimosis 10.0 BRCA1 BRCA2 TP53
49 mediastinum synovial sarcoma 10.0 BRCA1 BRCA2 TP53
50 cellular ependymoma 10.0 BRCA1 BRCA2 TP53

Graphical network of the top 20 diseases related to Uterine Corpus Serous Adenocarcinoma:



Diseases related to Uterine Corpus Serous Adenocarcinoma

Symptoms & Phenotypes for Uterine Corpus Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with cisplatin GR00101-A-4 8.96 BRCA1 BRCA2
2 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Uterine Corpus Serous Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.65 APRT BRCA1 BRCA2 ERBB2 TP53
2 digestive/alimentary MP:0005381 9.62 BRCA1 BRCA2 ERBB2 TP53
3 limbs/digits/tail MP:0005371 9.46 BRCA1 BRCA2 ERBB2 TP53
4 neoplasm MP:0002006 9.26 BRCA1 BRCA2 ERBB2 TP53
5 reproductive system MP:0005389 9.02 APRT BRCA1 BRCA2 ERBB2 TP53

Drugs & Therapeutics for Uterine Corpus Serous Adenocarcinoma

Drugs for Uterine Corpus Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
3
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Lenograstim Approved Phase 3,Phase 1 135968-09-1
6
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
7
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
8
Doxil Approved June 1999 Phase 3,Phase 1 31703
9 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
10 Antimitotic Agents Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
12 Adjuvants, Immunologic Phase 3,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Neuromuscular Agents Phase 3,Phase 2,Phase 1
17 Neuromuscular Blocking Agents Phase 3,Phase 2,Phase 1
18 Neuromuscular Depolarizing Agents Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 Hypoglycemic Agents Phase 2, Phase 3
21
Nintedanib Approved Phase 2 656247-17-5 56843413
22
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
23
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
24
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
25
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
26
Everolimus Approved Phase 2 159351-69-6 6442177
27
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
28
Trametinib Approved Phase 2 871700-17-3 11707110
29
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
30
Cediranib Investigational Phase 2 288383-20-0 9933475
31
Maleic acid Experimental Phase 2 110-16-7 444266
32
Epothilone B Experimental, Investigational Phase 2 152044-54-7
33
trebananib Phase 2
34 Angiogenesis Inhibitors Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 2,Phase 1
36 Immunoglobulin Fc Fragments Phase 2
37 Immunoglobulins Phase 2,Phase 1
38 Protein Kinase Inhibitors Phase 2
39 Antibodies Phase 2,Phase 1
40 Mitogens Phase 2,Phase 1
41 Endothelial Growth Factors Phase 2,Phase 1
42 Immunoglobulin G Phase 2,Phase 1
43 Anti-Infective Agents Phase 2,Phase 1
44 Antibodies, Monoclonal Phase 2,Phase 1
45 Antimalarials Phase 2
46 Antiparasitic Agents Phase 2
47 Antiprotozoal Agents Phase 2
48 Epothilones Phase 2
49 Immunosuppressive Agents Phase 2
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show all 31)
id Name Status NCT ID Phase
1 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
2 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3
3 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
4 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3
5 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
6 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2
7 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2
8 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2
9 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
10 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
11 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
12 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2
13 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
14 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Recruiting NCT02728258 Phase 2
15 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Active, not recruiting NCT01307631 Phase 2
16 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 2
17 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
18 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
19 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2
20 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT00888173 Phase 2
21 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2
22 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1
23 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1
24 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Recruiting NCT02142803 Phase 1
25 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1
26 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Active, not recruiting NCT00575952 Phase 1
27 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Not yet recruiting NCT03120624 Phase 1
28 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
29 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Active, not recruiting NCT02315469
30 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT01440998
31 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Uterine Corpus Serous Adenocarcinoma

Genetic Tests for Uterine Corpus Serous Adenocarcinoma

Anatomical Context for Uterine Corpus Serous Adenocarcinoma

Publications for Uterine Corpus Serous Adenocarcinoma

Variations for Uterine Corpus Serous Adenocarcinoma

Copy number variations for Uterine Corpus Serous Adenocarcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA Uterine serous papillary cancer

Expression for Uterine Corpus Serous Adenocarcinoma

Search GEO for disease gene expression data for Uterine Corpus Serous Adenocarcinoma.

Pathways for Uterine Corpus Serous Adenocarcinoma

Pathways related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 BRCA1 BRCA2 ERBB2 TP53
2 12.34 BRCA2 ERBB2 TP53
3
Show member pathways
12.33 BRCA1 BRCA2 TP53
4 12.16 BRCA1 ERBB2 TP53
5 12.14 BRCA1 BRCA2 TP53
6 11.69 BRCA1 BRCA2 TP53
7
Show member pathways
11.58 BRCA2 ERBB2 TP53
8 11.45 ERBB2 TP53
9 11.4 ERBB2 TP53
10 11.36 BRCA1 ERBB2
11 11.27 BRCA1 TP53
12
Show member pathways
11.25 BRCA1 BRCA2 TP53
13 11.2 BRCA1 TP53
14 11.17 BRCA1 TP53
15 11 BRCA1 ERBB2 TP53
16 10.98 BRCA1 TP53
17 10.95 BRCA1 TP53
18 10.9 BRCA1 TP53
19 10.65 BRCA1 TP53
20 10.62 BRCA1 ERBB2 TP53

GO Terms for Uterine Corpus Serous Adenocarcinoma

Cellular components related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.72 BRCA1 BRCA2 TP53
2 cell proliferation GO:0008283 9.7 BRCA2 ERBB2 TP53
3 positive regulation of gene expression GO:0010628 9.69 BRCA1 ERBB2 TP53
4 double-strand break repair via homologous recombination GO:0000724 9.56 BRCA1 BRCA2
5 double-strand break repair GO:0006302 9.54 BRCA1 BRCA2
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.49 BRCA1 BRCA2
7 nucleotide-excision repair GO:0006289 9.48 BRCA2 TP53
8 DNA synthesis involved in DNA repair GO:0000731 9.46 BRCA1 BRCA2
9 response to gamma radiation GO:0010332 9.43 BRCA2 TP53
10 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.4 BRCA2 TP53
11 cell aging GO:0007569 9.37 BRCA2 TP53
12 strand displacement GO:0000732 9.32 BRCA1 BRCA2
13 positive regulation of cell cycle arrest GO:0071158 9.26 BRCA1 TP53
14 response to X-ray GO:0010165 9.16 BRCA2 TP53
15 chordate embryonic development GO:0043009 8.96 BRCA1 BRCA2
16 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.96 ERBB2 TP53
2 damaged DNA binding GO:0003684 8.62 BRCA1 TP53

Sources for Uterine Corpus Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....